Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FTX-219
- Development stage
- Preclinical
- Lead developer
- Arterez
- Modality
- Small Molecules, Peptides
- Administration
- Oral
01
Overview
FTX-219 is a preclinical-stage small molecule and tripeptide derivative (specifically lipoate-cysteine-glutamic tripeptide) developed by Arterez. It is designed to restore and maintain the endothelial glycocalyx (GCX), a protective carbohydrate-rich layer lining the vascular endothelium. FTX-219 acts as an antioxidant and cytoprotective agent by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, which regulates the expression of antioxidant and cytoprotective genes. It is being developed for the treatment of cardiovascular disease, atherosclerosis, and viral infections (such as SARS-CoV-1), both as a monotherapy and as a component of the triple-combination therapy Embotricin (alongside FTX-214 and FTX-218).
- Other names
- lipoate-cysteine-glutamate tripeptidelipoate-cysteine-glutamic tripeptide
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on FTX-219.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FTX-219.